Nanotechnology

[shmoopy38]

Lumera Extends Collaborative Research Agreement with the Institute for Systems Biology

Collaboration to Focus on Predictive Biomarkers for both Drug
Toxicity and Cancer

BOTHELL, Wash.--(BUSINESS WIRE)--May 2, 2007--Lumera Corporation (NASDAQ:LMRA), a leader in the emerging field of nanotechnology, announced today that it has extended its collaboration agreement with the Institute for Systems Biology (ISB). The goal of the collaboration is to use Lumera's ProteomicProcessor(TM) to identify biomarkers associated with drug toxicity and cancer.

As previously announced, ISB researchers have demonstrated a label-free assay to determine protein expression patterns using a panel of specific antibodies printed on Lumera's NanoCapture-Gold(TM) microarray and analyzed on the company's ProteomicProcessor (TM) instrument system.

"We are quite pleased with the progress of the past year," said Dr. Leroy Hood, President of the Institute for Systems Biology. "Lumera's platform provides unique advantages in biomarker discovery and we are committed to moving the science forward."

"Early results from ISB have been proof positive that our technology adds significant value to the biomarker discovery market. We feel that with a continued emphasis on this project, we will arrive at a very important publication and will establish methods by which others will be able to develop their own assays," said Dr. Timothy Londergan, Lumera's Bioscience Business Unit.

As previously discussed by the company, biomarkers are important indicators of disease and their identification can lead to the development of targeted drug solutions to prevent or arrest the disease. Biomarker screening has been an increasing area of research growing from $5.4 billion in 2005 to an estimated $21 billion by 2012 according to Business Insights, a market research firm.

About Lumera

Lumera is an emerging leader in the field of nanotechnology. The company designs proprietary molecular structures and polymer compounds for a broad range of bioscience, electro-optic, and specialty nanotechnology applications. The company also has developed proprietary processes for fabricating such devices. For more information, please visit http://www.lumera.com/.

Certain statements contained in this release are forward-looking statements that involve a number of risks and uncertainties. Factors that could cause actual results to differ materially from those projected in the company's forward-looking statements include the following: market acceptance of our technologies and products; our ability to obtain financing; our financial and technical resources relative to those of our competitors; our ability to keep up with rapid technological change; government regulation of our technologies; our ability to enforce our intellectual property rights and protect our proprietary technologies; the ability to obtain additional contract awards and to develop partnership opportunities; the timing of commercial product launches; the ability to achieve key technical milestones in key products; and other risk factors identified from time to time in the company's SEC reports, including in its registrations statement on Form S-1, dated July 22, 2004 and its Quarterly Reports on Form 10-Q.


CONTACT: The Summit Group Communications
Todd Wolfenbarger, 801-595-1155
801-244-9600 cell

SOURCE: Lumera Corporation